We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial Future ... Pharmaceuticalscategory· 1:46 PM UTC Medical device maker Boston Scientific forecast annual profit above Wall ...

Alert FDA Warns About Diabetes Device Smartphone Alert Settings Changes ... 2025 Novo Nordisk to Seek Regulatory Approval for CagriSema Obesity Drug Early 2026 Novo Nordisk said on Wednesday ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Only 57.3% of patients in the CagriSema trial reached the highest dose, with Novo providing no explanation for the low figure. A trial participant lost 18% of her weight but reported severe side ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...